Company intelligence / Profile preview

UroMems

Grenoble, Auvergne-Rhône-Alpes, Franceuromems.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

UroMems has completed first-in-man and first-ever female feasibility studies of its UroActive™ smart artificial urinary sphincter. All patients reached six-month primary endpoints with no need for revision or explant after one year. The company reports very positive data on leak rates and quality of life, supporting pivotal clinical trials now being funded.

Therapeutic areas: Nephrology
Modalities: DeviceMechatronic implantable device (active implantable medical device)
Industry: Implantable Medical Devices

Drug pipeline

1 asset

UroActive

Phase 1

Indications: Stress urinary incontinence

Partnerships

European Innovation Councilcollaborations with research labs, hospitals, universities and industrial partners

Beyond the preview

Go deeper on UroMems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UroMems.

Explore the full profile